Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1α interaction with p300

Biochemical and Biophysical Research Communications

Volumn 434, Issue 4, 2013, Pages 879-884

  Na, Yu Ran ^a   Han, Ki Cheol ^a   Park, Hyunsung ^b   Yang, Eun Gyeong ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Seoul   (South Korea)

Author keywords

Ethacrynic acid; Hypoxia inducible factor 1 ; Menadione; P300; Small molecule inhibitor

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; ETACRYNIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; MENADIONE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE POLARIZATION; GENE TARGETING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

BINDING SITES; CELL HYPOXIA; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; E1A-ASSOCIATED P300 PROTEIN; ETHACRYNIC ACID; GENE EXPRESSION; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; LUCIFERASES; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RESPONSE ELEMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN K 3;

EID: 84878211420     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.044     Document Type: Article

References (32)

1. Vaupel P., Thews O., Kelleher D.K., Hoeckel M. Current status of knowledge and critical issues in tumor oxygenation. Results from 25 years research in tumor pathophysiology. Adv. Exp. Med. Biol. 1998, 454:591-602.
2. Vaupel P., Schlenger K.H., Hoeckel M., Okunieff P. Oxygenation of mammary tumors: from isotransplanted rodent tumors to primary malignancies in patients. Adv. Exp. Med. Biol. 1992, 316:361-371.
3. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer 2000, 36:1649-1660.
4. Koong A.C., Denko N.C., Hudson K.M., Schindler C., Swiersz L., Koch C., Evans S., Ibrahim H., Le Q.T., Terris D.J., Giaccia A.J. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000, 60:883-887.
5. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93:266-276.
6. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 1998, 95:7987-7992.
7. 2 sensing. Science 2001, 292:464-468.
8. Huang L.E., Bunn H.F. Hypoxia-inducible factor and its biomedical relevance. J. Biol. Chem. 2003, 278:19575-19578.
9. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003, 9:677-684.
10. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 2002, 64:993-998.
11. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 2007, 62:179-213.
12. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
13. Liao D., Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26:281-290.
14. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., Shen Y. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res. 2005, 65:7249-7258.
15. Yin S., Kaluz S., Devi N.S., Jabbar A.A., de Noronha R.G., Mun J., Zhang Z., Boreddy P.R., Wang W., Wang Z., Abbruscato T., Chen Z., Olson J.J., Zhang R., Goodman M.M., Nicolaou K.C., Van Meir E.G. Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1alpha Interaction with Cofactors p300/CBP. Clin. Cancer. Res. 2012, 18:6623-6633.
16. Liu L.P., Ho R.L., Chen G.G., Lai P.B. Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin. Cancer. Res. 2012, 18:5662-5671.
17. Yamaki A., Muratsubaki H. Phenazine methosulfate decreases HIF-1alpha accumulation during the exposure of cells to hypoxia. Biosci. Biotechnol. Biochem. 2012, 76:1682-1687.
18. Befani C.D., Vlachostergios P.J., Hatzidaki E., Patrikidou A., Bonanou S., Simos G., Papandreou C.N., Liakos P. Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J. Mol. Med. (Berl) 2012, 90:45-54.
19. Kwon H.S., Kim D.R., Yang E.G., Park Y.K., Ahn H.C., Min S.J., Ahn D.R. Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1alpha-p300 interaction by a small molecule. Bioorg. Med. Chem. Lett. 2012, 22:5249-5252.
20. Kallio P.J., Okamoto K., O'Brien S., Carrero P., Makino Y., Tanaka H., Poellinger L. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 1998, 17:6573-6586.
21. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., Bunn H.F., Livingston D.M. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 1996, 93:12969-12973.
22. Cho H., Ahn D.R., Park H., Yang E.G. Modulation of p300 binding by posttranslational modifications of the C-terminal activation domain of hypoxia-inducible factor-1alpha. FEBS Lett. 2007, 581:1542-1548.
23. Cho H., Lee H.Y., Ahn D.R., Kim S.Y., Kim S., Lee K.B., Lee Y.M., Park H., Yang E.G. Baicalein induces functional hypoxia-inducible factor-1alpha and angiogenesis. Mol. Pharmacol. 2008, 74:70-81.
24. Lee M.J., Kim J.W., Yang E.G. Hinokitiol activates the hypoxia-inducible factor (HIF) pathway through inhibition of HIF hydroxylases. Biochem. Biophys. Res. Commun. 2010, 396:370-375.
25. Li Y., Zhou X., St John M.A., Wong D.T. RNA profiling of cell-free saliva using microarray technology. J. Dent. Res. 2004, 83:199-203.
26. Lando D., Peet D.J., Whelan D.A., Gorman J.J., Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002, 295:858-861.
27. Cook K.M., Hilton S.T., Mecinovic J., Motherwell W.B., Figg W.D., Schofield C.J. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J. Biol. Chem. 2009, 284:26831-26838.
28. Block K.M., Wang H., Szabo L.Z., Polaske N.W., Henchey L.K., Dubey R., Kushal S., Laszlo C.F., Makhoul J., Song Z., Meuillet E.J., Olenyuk B.Z. Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine. J. Am. Chem. Soc. 2009, 131:18078-18088.
29. Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 2004, 279:9899-9904.
30. Ehrismann D., Flashman E., Genn D.N., Mathioudakis N., Hewitson K.S., Ratcliffe P.J., Schofield C.J. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem. J. 2007, 401:227-234.
31. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., Memmert K., Naegeli H.U., Petersen F., Eck M.J., Bair K.W., Wood A.W., Livingston D.M. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004, 6:33-43.
32. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl. 1):2-10.